Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Novel Strategy For Treating Obesity Suggested By Creation of Energy-Burning Brown Fat In Mice
Researchers at Dana-Farber Cancer Institute have shown that they can engineer mouse and human cells to produce brown fat, a natural energy-burning type of fat that counteracts obesity. If such a strategy can be developed for use in people, the scientists say, it could open a novel approach to treating obesity and diabetes. Don't forget to buy zoloft online no prescription.

Advances In Lab-Grown Motor Nerves Can Lead To Cures For Diabetic Neuropathy And Help Further Understand Multiple Sclerosis And Related Conditions
In the July issue of Biomaterials, published by Elsevier, researchers from the University of Central Florida (UCF) report on the first lab-grown motor nerves that are insulated and organized just like they are in the human body. The model system will drastically improve understanding of the causes of myelin-related conditions, such as diabetic neuropathy and later, possibly multiple sclerosis (MS). In addition, the model system will enable the discovery and testing of new drug therapies for these conditions.

generic viagra online


News of the day
The Battle For CRTC2: How Obesity Increases The Risk For Diabetes
Obesity is probably the most important factor in the development of insulin resistance, but science"s understanding of the chain of events is still spotty. Now, researchers at the Salk Institute for Biological Studies have filled in the gap and identified the missing link between the two. Their findings, to be published in the June 21, 2009 advance online edition of the journal Nature, explain how obesity sets the stage for diabetes and why thin people can become insulin-resistant.
Diagnostics

Insulin Glargine - European Medicines Agency Update On Safety

The European Medicines Agency"s Committee for Medicinal Products for Human Use (CHMP) has concluded that there is no cause for concern of the risk of cancer for people with diabetes on insulin glargine (Lantus). In June, studies published in "Diabetologia", the Journal of the European Association for the Study of Diabetes, suggested there may be a small increased risk of cancer in those taking glargine as their only insulin. The CHMP carried out an in-depth review of these studies and their outcomes. The studies were found to be inconclusive. In addition, the committee noted that the results of the studies were not consistent. Diabetes UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009